Barrier functional composition and oral composition
A synergistic composition of rosmarinic acid, caffeic acid, hesperetin, hesperidin, or their extracts with collagen peptide and vitamin C addresses skin barrier and moisture issues, enhancing skin elasticity and anti-aging effects.
Patent Information
- Application Number
- JP2022184449
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2022-11-17
- Publication Date
- 2024-11-20
- Estimated Expiration
- 2042-11-17
AI Technical Summary
Existing anti-aging solutions fail to effectively enhance skin barrier function and moisture retention, leading to issues such as dryness, wrinkles, and sagging due to UV rays, dryness, poor blood circulation, and nutritional deficiencies.
A barrier functional composition combining rosmarinic acid, caffeic acid, hesperetin, hesperidin, or their extracts with collagen peptide and vitamin C to synergistically improve skin barrier function.
The composition enhances skin barrier function, increases collagen and hyaluronic acid production, improves skin elasticity and moisture content, and provides anti-aging benefits by promoting collagen synthesis and strengthening the skin's structural integrity.
Smart Images

Figure 0007587562000001 
Figure 0007587562000002 
Figure 0007587562000003
Abstract
Description
[Technical field]
[0001] The present invention relates to a barrier functional composition having a barrier functional component, an oral composition (nutritional supplement) containing the barrier functional composition, and a food product containing the barrier functional composition as an active ingredient. [Background technology]
[0002] In the present invention, the barrier function refers to the barrier function of the skin, which plays a very important role in maintaining homeostasis in the body, that is, the internal environment of the skin, by preventing moisture in the body from evaporating out of the skin due to dryness and preventing foreign substances from entering the skin. Previous research has revealed that not only the stratum corneum of the epidermis but also tight junctions present in the granular layer of the epidermis play an important role in the barrier function of the skin. The skeleton of the tight junction strand is composed of cell membrane proteins claudin and occludin. It is known that a decrease in claudin and occludin causes the structure of the tight junction to collapse, hindering the barrier function against the permeation of substances, resulting in various skin symptoms such as dry skin and dermatitis. It is believed that by promoting the production of claudins and occludin, the formation of tight junctions in the epidermal keratinocytes in the granular layer is promoted, enhancing the barrier function and moisture retention function of the skin, thereby preventing or improving skin conditions such as rough skin and dry skin. To date, 27 types of claudin families have been identified in humans and mice.
[0003] In addition, amino acids, which are the main components of natural moisturizing factors, are produced by the decomposition of filaggrin derived from keratohyalin granules in the stratum corneum. This filaggrin is expressed as profilaggrin in epidermal keratinocytes present in the granular layer just below the stratum corneum. It is then immediately phosphorylated and accumulates in keratohyalin granules, where it is dephosphorylated and hydrolyzed before being decomposed into filaggrin. It has been reported that filaggrin then migrates into the stratum corneum, where it increases the aggregation efficiency of keratin filaments and is involved in the internal structure of keratinocytes. In recent years, it has been reported that filaggrin is extremely important and essential for maintaining moisture in the skin, and that conditions such as dryness reduce the ability to synthesize filaggrin, resulting in a decrease in the amount of amino acids in the stratum corneum. Therefore, it is expected that promoting the synthesis of filaggrin by promoting the expression of profilaggrin mRNA in epidermal keratinocytes will increase the amount of amino acids in the stratum corneum, improve the moisture environment of the stratum corneum, and strengthen the skin's barrier function.
[0004] The dermis is a tissue located inside the epidermis, and is mostly composed of collagen fibers, mucopolysaccharides such as elastin and hyaluronic acid, and fibroblasts, except for water. The firmness and elasticity of the skin are maintained by the collagen fibers, elastin, and hyaluronic acid in the dermis. The fibrous components of the dermis account for 90% of the skin, and are mainly produced by fibroblasts. Of these, type I collagen accounts for 80% of the collagen fibers that make up the dermis. Hyaluronic acid is widely distributed in the space surrounding fibroblasts in the dermis layer of the skin, and is localized in closely adjacent intercellular spaces in the epidermis layer, and is produced by dermal fibroblasts or epidermal keratinocytes. Of these, there are three types of hyaluronan synthase (HAS) in humans (HAS1, HAS2, HAS3), and it is known that HAS2 is mainly expressed in fibroblasts.
[0005] Previous studies have used various plant extracts (nettle leaf extract, Scutellaria root extract, It is known that essential oils (such as eucalyptus oil), fermented extracts obtained by fermenting plants with Aspergillus oryzae (artemisia plant fermented extract, thyme fermented extract, peppermint fermented extract, etc.) and essential oils (eucalyptus oil) improve the skin barrier function (Patent Documents 1, 2, 3, Non-Patent Document 1). [Prior art documents] [Patent documents]
[0006] [Patent Document 1] Patent Publication No. 2009-256244 [Patent Document 2] Patent Publication No. 2008-255051 [Patent Document 3] Patent Publication No. 2020-164486 [Non-patent literature]
[0007] [Non-Patent Document 1] "Elucidation of the effect of eucalyptus oil in enhancing epidermal barrier function," https: / / www.rohto.co.jp / research / researchnews / technologyrelease / 2021 / 0602_01 / , June 2, 2021 Summary of the Invention [Problem to be solved by the invention]
[0008] Ultraviolet rays, dryness, poor circulation and lack of nutrition accelerate skin aging, causing loss of firmness, elasticity and moisture, leading to wrinkles and sagging. In recent years, a lot of research has been conducted focusing on anti-aging. However, there has been no detailed mention of the promotion effect caused by the combination of new materials and conventional beauty ingredients.
[0009] Therefore, the object of the present invention is to identify a component that enhances the skin barrier function, and to provide a barrier functional composition that exerts a synergistic effect on the skin's barrier function by combining the barrier functional component with collagen peptide and vitamin C, as well as an oral composition or food containing the barrier functional composition. [Means for solving the problem]
[0010] As a result of extensive research, the inventors have identified a barrier functional ingredient and discovered a method of further improving the effects of the barrier functional ingredient and the barrier function of lemon balm extract by combining it with at least collagen peptides and vitamin C, thereby completing the following invention. That is, the present invention includes the following. 1. A barrier functional composition comprising rosmarinic acid or an extract containing rosmarinic acid, collagen peptide and vitamin C. 2. A barrier functional composition comprising caffeic acid or a caffeic acid-containing extract, collagen peptide and vitamin C. 3. A barrier functional composition comprising at least one member selected from the group consisting of hesperetin, a hesperetin-containing extract, hesperidin and a hesperidin-containing extract, as well as collagen peptide and vitamin C. 4. A barrier functional composition containing at least two of the group consisting of rosmarinic acid or a rosmarinic acid-containing extract, caffeic acid or a caffeic acid-containing extract, hesperetin or a hesperetin-containing extract, and hesperidin or a hesperidin-containing extract, as well as collagen peptide and vitamin C. 5. A barrier functional composition containing lemon balm extract, collagen peptide and vitamin C. 6. A composition for oral administration comprising the barrier functional composition according to any one of 1 to 5 above. 7. A food product comprising the barrier functional composition according to any one of 1 to 5 above as an active ingredient. Effect of the Invention
[0011] The barrier functional composition of the present invention, either by itself or in a food or oral composition containing it, exhibits the effect of isolating the internal environment of a living body from the external environment and ensuring homeostasis within the living body. More specifically, as will be apparent from the following examples, the barrier functional composition of the present invention contributes to improving skin wrinkles and elasticity by increasing the amount of collagen and hyaluronic acid in human dermal fibroblasts (Normal Human Dermal Fibroblasts: NHDFs), and at the same time acts on normal human epidermal keratinocytes (NHEKs), thereby strengthening the skin's barrier function, improving skin texture, and moisturizing the skin. Furthermore, when an oral composition made of the barrier functional composition or a food product containing the barrier functional composition as an active ingredient is ingested, each component acts comprehensively on the skin, increasing collagen density and skin moisture content, thereby strengthening the structure of the skin that has been weakened by natural aging. Furthermore, each item such as skin viscoelasticity and texture is greatly improved, which can provide further anti-aging effects such as improved epidermal barrier function. [Brief description of the drawings]
[0012] [Figure 1] Figure 1 shows the barrier function effect of plant extracts in NHEK. Graphs A and B show the change in gene expression of FLG and CLDN1 by the addition of lemon balm extract, respectively. Graph C shows the change in gene expression of FLG by the addition of licorice leaf extract. [Diagram 2] Figure 2 is a diagram verifying the barrier function of plant (lemon balm) extract components that have a barrier function effect in NHEK. A, B, C, and D are graphs showing the change in FLG gene expression in NHEK by the addition of rosmarinic acid, caffeic acid, hesperetin, and cynarosid, respectively. [Diagram 3]Figure 3 shows a photograph of immunofluorescence staining showing the localization of CLDN1 to verify the barrier function of the components of a plant (lemon balm) extract that has a barrier function effect in NHEK. The white arrow indicates the localization of CLDN1. [Figure 4] Figure 4 is a diagram verifying the synergistic effect of rosmarinic acid, caffeic acid, and hesperetin on the barrier function in NHEK. A is a graph showing the change in FLG gene expression caused by rosmarinic acid and a mixture of rosmarinic acid, collagen peptide, and vitamin C. B is a photograph of immunofluorescence staining showing the localization of CLDN1 caused by rosmarinic acid and a mixture of rosmarinic acid, collagen peptide, and vitamin C. The white arrow indicates the localization of CLDN1. C and D are graphs showing the change in FLG gene expression caused by caffeic acid, a mixture of caffeic acid, collagen peptide, and vitamin C, and by hesperetin, and a mixture of hesperetin, collagen peptide, and vitamin C, respectively. [Diagram 5] 5 is a diagram showing gene expression of FLG and CLDN1 in NHEKs for collagen peptide, vitamin C, and a mixture of collagen peptide and vitamin C. A is a graph showing the change in FLG, and B is a graph showing the change in CLDN1. [Figure 6] FIG. 6 shows photographs of immunofluorescence staining showing the localization of CLDN1 in NHEK treated with collagen peptide, vitamin C, and a mixture of collagen peptide and vitamin C. [Figure 7] Figure 7 is a diagram verifying the synergistic effect of lemon balm extract on barrier function in NHEK. A is a graph showing the change in FLG gene expression caused by lemon balm extract and a mixture of lemon balm extract, collagen peptide, and vitamin C. B is a photograph of immunofluorescence staining showing the localization of CLDN1 caused by lemon balm extract and a mixture of lemon balm extract, collagen peptide, and vitamin C. The white arrow indicates the localization of CLDN1. [Figure 8]Figure 8 is an examination of the barrier function effects of plant extracts. Graphs A and B show the changes in FLG gene expression caused by licorice leaf extract and a mixture of licorice leaf extract, collagen peptide, and vitamin C, as well as the changes in FLG gene expression caused by eucalyptus leaf oil and a mixture of eucalyptus leaf oil, collagen peptide, and vitamin C, respectively. [Figure 9] Figure 9 shows immunofluorescence staining images showing the localization of CLDN1 to verify the barrier function effect of the plant extract in NHEK. The white arrow indicates the localization of CLDN1. [Figure 10] Figure 10 is a diagram verifying the type I collagen production and hyaluronic acid production abilities in NHDF by a mixture of lemon balm extract, collagen peptide, and vitamin C. A and B are the results of Western blotting showing the increase in COL1A1 and HAS2 expression by the mixture, respectively. [Figure 11] Figure 11 shows the results of a three-dimensional skin model using a mixture of lemon balm extract, collagen peptide, and vitamin C. A and B are graphs showing the changes in gene expression of FLG and HAS3, respectively. C is a visual observation photograph evaluating the effect on melanin production and a quantitative graph of melanin content. [Figure 12] Figure 12 shows the results of improving skin condition by oral intake of a mixture of lemon balm extract, collagen peptide, and vitamin C. A is a graph showing collagen density at 0, 2, and 4 weeks after oral intake, and an image of collagen density on the cheek. B is a graph showing the change in skin moisture content at 0, 2, and 4 weeks after oral intake, measured by Corneometer (registered trademark). [Figure 13] Figure 13 shows the results of improving skin condition by oral intake of a mixture of lemon balm extract, collagen peptide, and vitamin C. A and B are graphs showing skin viscoelasticity and photographs showing cheek texture at 0, 2, and 4 weeks after oral intake, respectively. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0013] The present invention provides a barrier functional composition which contains a barrier functional ingredient or lemon balm extract, collagen peptide and vitamin C, and which exerts a synergistic effect on the skin's barrier function when mixed together, an oral composition comprising the barrier functional composition, and a food product containing the barrier functional composition as an active ingredient. The present invention will be described in detail below, but it should be understood that the present invention is not limited to the following specific embodiments and can be modified as desired within the scope of the technical concept.
[0014] [Constituents of plant extracts that can improve skin barrier function] It is said that some plant extracts may be related to the skin barrier function. The inventors further analyzed in detail the components of plant extracts that have such barrier function. In the detailed description of the present invention, the constituent components of lemon balm extract have been described, but the same compounds can exhibit the same functions regardless of their origin.
[0015] Lemon balm, also known as melissa or mint, is a perennial plant of the Lamiaceae family that has been used to flavor foods and beverages, and in folk medicine as an herb or essential oil. It is said to have sedative, antidepressant, and antibacterial effects, but scientific verification has not progressed much. There are no particular restrictions on the parts of lemon balm that can be used as raw materials for producing lemon balm extract. For example, leaves, stems, roots, flowers, fruits, peels, pits, whole plants, and mixtures of these can be used, with leaves being the most preferable.
[0016] Lemon balm leaf extract (lemon balm extract) is known to contain rosmarinic acid, caffeic acid, hesperetin, m-coumaric acid, naringin, luteolin, hesperidin, naringenin, cynarroside, pyracanthoside, etc., and its main component is rosmarinic acid. (96.45±0.13 mg / g) (LWT(2008)41,391-399, Planta Med.(1999)65(6)576-8).
[0017] Rosmarinic acid Rosmarinic acid is a water-soluble natural phenolic acid compound that is found mainly in plants of the Lamiaceae family, such as rosemary, lemon balm, and mint. It is also a natural antioxidant with strong antioxidant activity that prevents cell damage caused by free radicals and reduces the risk of cancer and arteriosclerosis, and has a strong anti-inflammatory effect, showing important application value in fields such as pharmacology, food, and cosmetics. Furthermore, as a functional ingredient derived from natural plants, it is attracting attention as an edible material due to the health-conscious trend.
[0018] Caffeic acid Caffeic acid is a type of polyphenol that is widely distributed in various plants such as coffee, cypress, artichoke, and honeysuckle. It has been recognized to have pharmacological effects such as relaxation effects, anticancer effects, antiviral and antibacterial effects, antioxidant effects, and lipid and blood sugar regulation.
[0019] Hesperetin and Hesperidin Hesperetin is a natural flavonoid found widely in fruits, flowers, and other plants. It is expected to have antioxidant, anti-cancer, and anti-allergic effects, as well as improve blood cholesterol levels, and is widely used in many fields, including medicine, agriculture, and food. Hesperidin is a rutinose glycoside of hesperetin and is classified as a type of polyphenol. It is found in large amounts in citrus fruits such as mandarins, and is known for its antioxidant effects and for strengthening peripheral blood vessels. Hesperetin is derived mainly from the hydrolysis of hesperidin and has the same physiological functions as hesperidin. Lemon balm extract contains both hesperetin and hesperidin.
[0020] Luteolin and Cynarosides Luteolin is a type of natural flavonoid found in various plants. It is said to have various pharmacological activities, such as suppressing the rise of uric acid levels, antioxidant effects, antiviral and antibacterial effects, antiallergic effects, and anti-inflammatory effects. Cynarroside, also known as luteolin-7-O-glucoside, is a glucose glycoside of luteolin. It is also a type of flavonoid and has antioxidant, antiviral and antibacterial properties.
[0021] Naringenin Naringenin is a type of flavonoid classified as flavanone. It is known to be contained in various fruits and herbs, including citrus fruits such as tomatoes and grapefruit. It has antibacterial, antiviral, anti-inflammatory, antioxidant, and anticancer effects, and is widely used in medicine, food, and other fields.
[0022] [Verification of the barrier function of plant extracts] Previous studies have demonstrated that claudins are extremely important for the barrier function in normal human epidermal keratinocytes. Filaggrin is a protein present in the stratum corneum that plays an important role in the skin barrier function. Therefore, the effects on the barrier function can be evaluated by examining the changes in the gene expression of claudin 1 (CLDN1) and filaggrin (FLG), which are members of the claudin family.
[0023] For example, as shown in Figure 1, gene expression of FLG and CLDN1 in NHEK was increased in a concentration-dependent manner by lemon balm extract. Expression of FLG has also been confirmed by the addition of licorice leaf extract, which is known to be an extract of licorice root.
[0024] [Barrier functional ingredients] We investigated whether several components contained in lemon balm extract have an effect on barrier function. Figure 2 shows the barrier function of the components contained in lemon balm extract in NHEK. It was confirmed that the addition of four types of extract, rosmarinic acid, caffeic acid, hesperetin, and cynarosid, increased FLG gene expression. Figure 3 shows a photograph showing the localization of CLDN1 using immunofluorescence staining to verify the barrier function of the components contained in lemon balm extract in NHEK. The localization of CLDN1 in the cell membrane was confirmed with rosmarinic acid, caffeic acid, naringenin, hesperetin, and luteolin. Therefore, it is clear that the above ingredients act on the barrier function.
[0025] Here, the barrier functional component applied in the present invention can typically be confirmed by adding the component to skin cells and observing concentration-dependent enhancement of intracellular FLG or CLDN1 gene expression, or observing localization of CLDN1 in the cell membrane by immunofluorescence staining. Each component, such as rosmarinic acid, caffeic acid, naringenin, hesperetin, and luteolin, corresponds to the barrier functional component of the present invention.
[0026] [Barrier functional composition] The barrier function composition of the present invention contains, in addition to the above-mentioned barrier function ingredient, at least a collagen peptide and vitamin C. By combining the barrier function ingredient with the collagen peptide and vitamin C, a synergistic effect of the barrier function can be confirmed. The synergistic effect of barrier function is shown, for example, in that a mixture containing a barrier functional component, collagen peptide, and vitamin C shows a doubling in the gene expression of CLDN1 and FLG compared to the case of the barrier functional component alone.
[0027] [Collagen peptide] Collagen is a protein that mainly constitutes the dermis, ligaments, tendons, bones, cartilage, etc. of vertebrates, and it has been reported that at least 29 different types of collagen exist in the human body. Type I collagen, in which a total of three polypeptide chains, two α1 chains and one α2 chain, form a triple helix structure, is the most abundant in the body. The collagen in the present invention may be any type of collagen, and its origin is not particularly limited, but collagen from animals (such as cows, pigs, and birds) or fish (such as tilapia) is preferred. Collagen peptides are obtained by hydrolyzing natural collagen and further reducing the molecular weight by enzymatic, acidic or alkaline decomposition depending on the circumstances. Collagen peptides are also produced synthetically. The collagen peptides contained in the barrier functional composition of the present invention can be produced by the above-mentioned known methods. The weight average molecular weight is preferably 100 to 20,000.
[0028] [Vitamin C] Vitamin C is an essential nutrient for humans and one of the most widely used vitamins. It boosts the body's immune system, is involved in collagen synthesis and cholesterol metabolism, and also acts as an antioxidant. Since vitamin C cannot be produced in the body, it is either ingested from fresh vegetables and fruits, or is commonly used in food and drinking water for nutritional purposes. Natural or synthetic (including derivative) vitamin C can also be used.
[0029] [Oral composition comprising a barrier functional composition] The present invention further provides an oral composition comprising a barrier functional composition. The barrier functional composition may further contain other nutritional components, such as amino acids, as long as the effect of the barrier function is not inhibited. It may contain acids, sugars, proteins, fatty acids, vitamins, minerals, etc., and / or health food ingredients.
[0030] Examples of health food ingredients include vitamin B derivatives, theanine, γ-aminobutyric acid (GABA), anserine, soybean peptides, thioredoxin, wheat gluten hydrolysates, glutamine, milk peptides, ω-3 fatty acids (docosahexaenoic acid, eicosapentaenoic acid, etc.), phosphatidylserine, astaxanthin, pycnogenol, flavangenol, creatine, carnitine, α-lipoic acid, polyphenols, green tea catechins, saponin, N-acetylglucosamine, lignans (sesamin, etc.), herbs, crude drugs, mushrooms, algae, dietary fiber, fruit juice and fruit powder, lactic acid bacteria, bifidobacteria, koji mold, yeast, etc. These can be used alone or in combination of two or more types.
[0031] Examples of herbs include rafuma, Eleuthero, wasabi, Italian parsley, ericampane, olive, oregano, currant, chamomile, curry plant, catnip, caraway, Christmas rose, crimson clover, cornflower, common mallow, salad burnet, santolina, cinnamon, jasmine, stevia, sage, linden, scented geranium, St. John's wort, soapwort, Solomon's seal, thyme, tansy, chervil, chives, nasturtium, jujube, basil, and honey. Examples of herbs include, but are not limited to, succulent, hyssop, flax, fennel, foxglove, blackley hollyhock, French marigold, betony, heliotrope, bergamot, hemp agrimony, common rue, pot marigold, borage, white horehound, myrtle, mullein, marjoram, mint, yarrow, lavender, lady's bedstraw, lemongrass, lemon verbena, rose, rosemary, rocket, wild strawberry, wild pansy, and forget-me-not.
[0032] Examples of herbal medicines include, but are not limited to, ginkgo, fennel, turmeric, licorice, camphor, bellflower, chrysanthemum, goldenrod, lycium, lily of the valley, kettle, cinnamon, and rhododendron amplexicaule.
[0033] Examples of mushrooms include, but are not limited to, Matsutake, Maitake, Shiitake, Enoki, Shimeji, King Oyster Mushroom, and Bunaharitake.
[0034] Examples of algae include processed products (extracts, dried and ground powders, fermented products, etc.) of spirulina, chlorella, euglena, etc., but are not limited thereto.
[0035] Examples of dietary fiber include, but are not limited to, indigestible dextrin, maltodextrin, isomaltodextrin, dried soybean pulp, soybean dietary fiber, and apple dietary fiber.
[0036] Fruit juices include, but are not limited to, orange, mango, grapefruit, grape, peach, pineapple, apple, pomegranate, pear, strawberry, acerola, kiwi fruit, and the like. Fruit powders include, but are not limited to, banana powder, mango powder, apple powder, kiwi powder, cranberry powder, mulberry powder, blueberry powder, lemon juice powder, orange juice powder, peach juice powder, grapefruit juice powder, pineapple juice powder, pomegranate juice powder, acai powder, acerola powder, and the like.
[0037] Lactic acid bacteria include dead bacteria, live bacteria, and fermented products. Examples include Enterococcus faecalis, Lactobacillus casei, Lactobacillus acidophilus, Lactobacillus planifolius, and Lactobacillus casei. Examples of such bacteria include, but are not limited to, Lactobacillus thalum, Lactobacillus paracasei, Lactobacillus rhamnosus, Lactococcus lactis, and Lactobacillus brevis. Bifidobacteria include killed, live and fermented forms of bifidobacteria, including, but not limited to, Bifidobacterium breve, Bifidobacterium bifidum and Bifidobacterium longum. Koji mold includes dead bacteria, live bacteria, and fermented products. For example, grain koji is one example. Yeast includes dead cells, live cells, fermented products, and extracts.
[0038] The barrier functional composition of the present invention may further contain vitamin B, vitamin C, vitamin E, derivatives thereof, and antioxidants and / or antioxidant enzymes other than the barrier functional component of the present invention. The antioxidant is not particularly limited, but examples thereof include probucol, lycopene, astaxanthin, carotenoids, flavonoids, polyphenols, glutathione, selenium, etc. These may be used alone or in combination of two or more kinds.
[0039] Examples of antioxidant enzymes include, but are not limited to, superoxide dismutase (SOD), glutathione peroxidase, glutathione-S-transferase, glutathione reductase, catalase, ascorbic acid peroxidase, etc. These may be used alone or in the form of a mixture of two or more kinds.
[0040] The oral composition comprising the barrier functional composition of the present invention may contain one or more suitable combinations of the antioxidants, antioxidant enzymes, and health food materials exemplified above.
[0041] The oral composition may be in the form of, but is not limited to, granules, powder, capsules, and tablets.
[0042] The amounts of barrier functional ingredient, collagen peptide, and vitamin C in the oral composition of the present invention are, for example, formulated so that per daily intake, the amount of one type of barrier functional ingredient is in the range of 0.01 to 700 mg, the amount of collagen peptide is in the range of 100 to 20,000 mg, and the amount of vitamin C is in the range of 10 to 1,000 mg.
[0043] The amounts of lemon balm extract, collagen peptide, and vitamin C in the oral composition of the present invention are, for example, per daily intake, such that the amount of lemon balm extract is in the range of 1 to 500 mg, the amount of collagen peptide is in the range of 100 to 20,000 mg, and the amount of vitamin C is in the range of 10 to 1,000 mg.
[0044] The daily allowable intake of vitamin C for adults is 2000mg. In contrast, no allowable intake is set for barrier functional ingredients, lemon balm extract, and collagen peptides. As long as the daily intake of vitamin C does not exceed the allowable intake, there is no particular limit to the number of times it can be taken, but it is recommended to take it once a day or less.
[0045] [Food containing a barrier functional composition as an active ingredient] Foods containing the barrier functional composition of the present invention as an active ingredient include those in which the barrier functional composition is made into food or blended into food, and can take the form of general food. There is no particular limit to the type of food provided or blended, and examples of such foods include liquid (fluid) foods such as jelly drinks, soft drinks, soups, dairy products, and seasonings, as well as rice, bread, noodles, and confectionery. Depending on the application, the composition may be formed into, but is not limited to, beverages, bars, granules, powders, capsules, and tablets. Furthermore, as necessary, the composition may be appropriately mixed with excipients, binders, thickening stabilizers, emulsifiers, colorants, flavorings, seasonings, acidulants, sweeteners, and the like, within the scope that does not impair the effects of the present invention. The amount of the barrier functional composition or lemon balm extract added to the above food is the same as that of the oral composition. The daily allowable intake of vitamin C for adults is 2000 mg, but no allowable intake is set for the barrier functional ingredient or collagen peptide. EXAMPLES
[0046] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.
[0047] Abbreviation: pep: collagen peptide VC: Ascorbic acid (vitamin C) LB: Lemon balm extract Licorice: Licorice leaf extract Yu: Eucalyptus leaf oil RA: Rosmarinic acid CA: Caffeic acid Hst: Hesperetin
[0048] (Lemon balm extract) The extract of lemon balm extract can be easily obtained by carrying out an extraction process using a method generally used for plant extraction. The form of the raw material for extraction is not particularly limited and can be appropriately selected according to the purpose, but it is preferable to use one that is dried and crushed immediately after collection. The solvent used for extraction is not particularly limited and can be appropriately selected according to the purpose. For example, it is preferable to use water, an organic solvent, or a mixed solvent thereof at room temperature or a temperature below the boiling point of the solvent. Alternatively, a commercially available product such as Lemon Balm Extract Powder MF (Maruzen Pharmaceutical Co., Ltd.) may be used.
[0049] (cell culture) All cells and media were purchased from Thermo Fisher Scientific. NHEK medium was EpiLife TM The medium for NHDF was Medium 106 with the addition of Low Serum Growth Supplement (LSGS). Both cells were cultured at 37°C in 5% CO2.
[0050] (Plant extract processing, barrier functional ingredient processing and protein extraction) Cells were plated in 6-well culture plates at 1 x 10 cells per well. 5 Cells were seeded and incubated at 37°C, 5% The cells were cultured overnight under CO2 conditions. After that, the specified concentrations of plant extracts and active ingredients were added and the cells were cultured statically under the specified conditions. After treatment with the plant extracts and active ingredients, the cells were washed twice with phosphate buffer and then moved on to the next step. Protein extraction was performed by lysing the cells with an extraction buffer (25 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS) and protease inhibitors) to obtain a protein extract.
[0051] (Western blotting) The protein extract was diluted with a buffer dedicated to SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and boiled at 95°C for 5 min. The obtained samples were separated by SDS-PAGE using a gel containing 10% polyacrylamide, and further transferred to a polyvinylidene difluoride membrane (PVDF membrane) using a semi-dry blotter (Bio-Rad). The transfer membrane was blocked in phosphate buffer containing 5% skim milk at room temperature for 1 hour. The PVDF membrane was then washed three times with Tris-Buffered Saline (TBS-T) containing Tween 20 and reacted overnight at 4°C with COL1A1 (Millipore) or HAS2 (Santa Cruz Biotechnology) antibodies diluted to the specified concentrations. The PVDF membrane was washed three times with TBS-T and reacted with a secondary antibody (Santa Cruz Biotechnology or Abcam) labeled with Horseradish peroxidase (HRP) diluted to a specified concentration at room temperature for 1 hour. After washing three times with TBS-T, signals were detected using the ECL Plus Western Blotting Detection System (Cytiva) as a detection reagent and the LAS-3000 (Cytiva) as a detection device. Actin was detected in the same manner using an Actin antibody (Abcam) as a standard protein.
[0052] (Measurement of gene expression levels using real-time quantitative PCR) RNA was extracted from the collected samples from various cells using the RNeasy Mini Kit (QIAGEN). The procedure was performed according to the manufacturer's recommended method. cDNA was prepared from the RNA thus obtained using the PrimeScript II 1st strand cDNA Synthesis Kit (Takara Bio). The procedure was performed according to the manufacturer's recommended method. The expression of FLG, CLDN1, and HAS3 genes was evaluated by real-time quantitative PCR (qPCR) using a probe method. The probes were predesigned TaqMan メ Gene Expression Assays (Thermo Fisher Scientific) were used. FLG was Hs00856927_g1, CLDN1 was Hs00221623_m1, HAS3 was Hs00193436_m1, and the endogenous control was β-actin (ACTB) Hs01060665_g1. メ The 7500 Real Time PCR System (Thermo Fisher Scientific) was used as the measurement device. All operations were performed according to the method recommended by the manufacturer.
[0053] (Immunofluorescence staining) NHEK cells were seeded on a culture dish containing collagen-coated cover glass, and pre-cultured in EpiLife medium for 24 hours. Various components and plant extracts were then added to the desired final concentrations, and the cells were cultured for a further 72 hours. After the culture was completed, the collected cover glass was placed in 4% paraformaldehyde in phosphate buffer and left at room temperature for 15 minutes to fix the cells. The cover glass was washed three times with phosphate buffer, and then fixed with 0.1% Triton X-rays. TMThe sections were then washed three times with phosphate buffer, and then placed in phosphate buffer containing 3% bovine serum albumin (BSA), and left at room temperature for 10 minutes to perform permeabilization. After washing three times with phosphate buffer, the sections were placed in phosphate buffer containing 3% bovine serum albumin (BSA), and left at room temperature for 1 hour to perform blocking. Claudin-1 antibody (Invitrogen) diluted to a specified concentration with phosphate buffer containing 1% BSA was then added and reacted overnight at 4°C. After washing three times with phosphate buffer, fluorescently labeled secondary antibody (Thermo Fisher Scientific) was diluted to a specified concentration with phosphate buffer containing 1% BSA, and reacted at room temperature for 1 hour. Next, to stain the nuclei, the sections were washed three times with PBS, and then placed in phosphate buffer containing 2 μg / ml 4',6-diamidino-2-phenylindole (DAPI) (Dojindo Chemical Industries) and left for 5 minutes. After washing three times with phosphate buffer, the sections were mounted using Fluoromount (Diagnostic Biosystems). After drying, the cell morphology was observed using a confocal laser microscope (TCS SP2 AOBS, Leica Microsystems).
[0054] (3D skin model) The three-dimensional skin model used was the MatTec MEL-300 model (derived from a black donor) composed of NHEK and human skin pigment cells (normal human dermal melanocyte, NHEM). The procedure was performed according to the method recommended by the manufacturer. For the test system assuming oral ingestion, the test substance was added to the medium, and after culturing for a certain period of time, gene fluctuations, protein localization, and melanin amount were verified. The three-dimensional skin model used can also be prepared and used by a known method (J. Invest. Dermatol., 104(1), 107-112, 1995).
[0055] (Melanin quantification) The amount of melanin in the three-dimensional skin model was quantified by absorbance measurement. First, cells were collected from the cell culture insert and washed twice with phosphate buffer. The collected cells were washed in the order of 5% trichloroacetic acid, ethanol / diethyl ether (3 / 1), and diethyl ether, and air-dried at 55°C for 1 hour. Then, the cells were placed in a SOLVABLE TM (PerkinElmer) was added and dissolved by heating at 80℃ for 30 minutes, and the absorbance of the supernatant at 405 nm was measured using a microplate reader. The total protein amount of each sample was also measured, and the melanin amount of each sample was corrected by the protein amount to calculate the melanin amount per cell. The total protein can be quantified by any method such as the BCA method, the Bradford method, or the Lowry method, and the correction method is not limited to the protein amount, and cell viability by MTT assay or the like can also be used.
[0056] (Verification of human skin condition upon oral ingestion) A four-week open-label study was conducted on 17 women in their 30s to 50s. The subjects consumed one bottle of a drink containing collagen peptides, vitamin C, and lemon balm extract per day, and their skin condition was measured before the start of the study (0 weeks after intake), after two weeks, and after four weeks. After washing their faces with lukewarm water, the subjects were allowed to acclimate for 15 minutes in an environmental testing room (temperature 25±2°C, humidity 55±5%), and then four items were measured: skin moisture, collagen density, skin viscoelasticity, and skin texture images were taken. The equipment used is described below. The measurement method followed the protocol of the equipment. Collagen density: DermaLab (Cortex Technology) Skin moisture content: Corneometer CM825 (Courage+Khazaka) Skin viscoelasticity: Cutometer DUAL MPA580 (Courage+Khazaka) Texture image: i-SCOPE USB2.0 (Made by Moritex)
[0057] (statistical analysis) Statistical analysis was performed using the Tuley-Kramer multiple comparison test. P values less than 0.05 were considered statistically significant.
[0058] [Example 1: Synergistic effect of barrier function (barrier functional ingredient)] Collagen peptides and vitamin C are known to have various skin-beautifying effects, such as maintaining elasticity in skin cells and whitening. A synergistic effect of barrier function was confirmed in a mixture in which collagen peptides and vitamin C were added to the barrier functional ingredient.
[0059] As shown in Figure 4, the mixture of rosmarinic acid, collagen peptides, and vitamin C increased FLG gene expression by nearly two-fold compared to the mixture of rosmarinic acid alone (Figure 4A). Immunofluorescence staining also showed that the localization of CLDN1 in the mixture was higher than that of rosmarinic acid alone. It was shown that the expression of β-lactamase was enhanced compared to that of β-lactamase (Fig. 4B). Furthermore, in the case of a mixture of caffeic acid, collagen peptides, and vitamin C, as well as a mixture of hesperetin, collagen peptides, and vitamin C, it was shown that FLG gene expression was enhanced compared to caffeic acid and hesperetin alone, respectively (Figure 4C and Figure 4D).
[0060] As shown in Figures 5 and 6, gene expression of FLG and CLDN1 acting on NHEK, and intracellular localization of CLDN1 did not change even when collagen peptide and vitamin C were added simultaneously. In other words, it can be said that collagen peptide, vitamin C, and a mixture of collagen peptide and vitamin C do not directly act on the barrier function of cells.
[0061] In other words, it is clear that adding a mixture of a barrier functional ingredient, collagen peptide and vitamin C to skin cells can provide superior barrier function compared to the case where only the barrier functional ingredient is added.
[0062] [Example 2: Synergistic effect of barrier function (plant extract)] The inventors of the present application confirmed that a mixture of lemon balm extract, collagen peptide, and vitamin C, which have barrier function, has a more excellent barrier function than lemon balm extract alone. This is shown in Figure 7. Figure 7A is a graph showing the change in FLG gene expression caused by lemon balm extract and a mixture of lemon balm extract, collagen peptide, and vitamin C. In the case of lemon balm extract alone, FLG gene expression was already more than 10 times higher than the control. In the case of the mixture of lemon balm extract, collagen peptide, and vitamin C, FLG gene expression was confirmed to be more than 2.5 times higher than that of lemon balm extract alone. In addition, the immunofluorescence staining photograph shown in Figure 7B confirmed the synergistic effect of the mixture of the three components on the localization of CLDN1, which is related to barrier function, in the cell membrane.
[0063] The inventors of the present application also examined other plant extracts that are said to have the same barrier function, such as licorice leaf extract and eucalyptus leaf oil. The FLG gene expression was reduced when licorice leaf extract was added in a ternary mixture with collagen peptide and vitamin C compared to when it was added alone (Figure 8A). Furthermore, no enhancement of barrier function was confirmed by the ternary mixture of collagen peptide and vitamin C in terms of the localization of CLDN1 (Figure 9). When eucalyptus leaf oil was added alone, no increase in FLG gene expression was observed (FIG. 8B), and no localization of CLDN1 was confirmed (FIG. 9). In addition, mass spectrometry was used to determine whether licorice leaf extract and eucalyptus leaf oil contained rosmarinic acid, caffeic acid, and hesperetin, and it was confirmed that neither contained these components.
[0064] In other words, only certain plant extracts exhibit a clear synergistic effect on the skin's barrier function when collagen peptides and vitamin C are added simultaneously.
[0065] [Example 3 Verification of collagen production ability and hyaluronic acid production ability] Using NHDF, we investigated the effects of a mixture of lemon balm extract, collagen peptides, and vitamin C on these production abilities. Figures 10A and B show the results of Western blotting, which show that the addition of a mixture of lemon balm extract, collagen peptide, and vitamin C increased the levels of COL1A1 and HAS2 proteins. Increases in collagen and hyaluronic acid production in NHDF were confirmed.
[0066] [Example 4 Verification using a three-dimensional skin model] Three-dimensional skin models have a structure similar to human skin tissue and are widely used in place of human skin when evaluating safety and efficacy. Using the three-dimensional skin model, we investigated the effects of a mixture of lemon balm extract, collagen peptides, and vitamin C on the skin's barrier function and hyaluronic acid production.
[0067] Figures 11A and B are graphs showing the changes in gene expression of FLG and HAS3 due to a mixture of lemon balm extract, collagen peptide, and vitamin C. These results show that the mixture increased the expression of FLG and HAS3. In other words, it is strongly suggested that the mixture enhances the skin barrier function and hyaluronic acid production ability related to moisturizing.
[0068] Figure 11C is a photograph and graph showing a comparison of melanin production in three-dimensional skin tissue using a mixture of lemon balm extract, collagen peptide, and vitamin C. Forskolin was added as a melanin production promoter. It was newly confirmed that these mixtures have skin barrier function, collagen production ability, hyaluronic acid production ability, and also melanin production inhibition ability.
[0069] [Example 5 Open-label study of oral intake] Not only in in vitro tests using cells, but also when taken orally by humans, a mixture of collagen peptides, vitamin C, and lemon balm extract was shown to have the effect of strengthening the barrier function, improving skin texture, and moisturizing the skin.
[0070] The subjects consumed one bottle of a drink containing collagen peptides, vitamin C, and lemon balm extract per day, and their skin condition was measured before (0 weeks after ingestion), after 2 weeks, and after 4 weeks of ingestion. The results are shown in Figures 12 and 13. Figure 12 shows the collagen score, an index of collagen density, and skin moisture content. It was significantly increased on the forearm after four weeks of drinking, and on the cheek after both two and four weeks of drinking (Figure 12A). After two weeks of drinking, skin moisture content tended to increase on the cheek, temple, and forearm, and after four weeks of drinking, it was significantly increased on the cheek (Figure 12B). Figure 13 shows the changes in skin viscoelasticity and cheek texture due to continued drinking. A significant increase in skin viscoelasticity was observed on the forearm after four weeks of drinking (Figure 13A). Furthermore, it was confirmed that skin texture improved (Figure 13B). In other words, it was shown that a mixture of collagen peptides, vitamin C and lemon balm extract is effective not only in cells, but also when taken orally by humans.
[0071] Collagen peptides are used in collagen synthesis in the body, and vitamin C is essential for this synthesis process. It has also been suggested that lemon balm extract has the effect of promoting the uptake of decomposed collagen into fibroblasts. Therefore, it was thought that taking collagen peptides and vitamin C at the same time promoted collagen synthesis in the body, and that mixing the three ingredients, including lemon balm extract, further enhanced this effect. [Industrial Applicability]
[0072] It has been revealed that collagen peptides, vitamin C, and barrier functional ingredients or barrier functional compositions contribute to improving wrinkles and elasticity of the skin by increasing the amount of collagen and hyaluronic acid in fibroblasts in the dermis layer of the skin. At the same time, it has been newly suggested that they also act on keratinocytes in the epidermis layer, and have the functions of strengthening the barrier function of the skin, improving texture, and moisturizing. It is believed that by taking these ingredients in combination, they act comprehensively on the skin, strengthening the structure of the skin that has been weakened by natural aging, and further anti-aging effects such as improving the epidermal barrier function can be expected.
Claims
1. A barrier functional composition for promoting FLG gene expression in human epidermal keratinocytes, characterized by containing rosmarinic acid or a rosmarinic acid-containing extract, collagen peptides and vitamin C.
2. A barrier functional composition for promoting FLG gene expression in human epidermal keratinocytes, characterized by containing caffeic acid or a caffeic acid-containing extract, collagen peptide and vitamin C.
3. A barrier functional composition for promoting FLG gene expression in human epidermal keratinocytes, characterized by containing at least one member of the group consisting of hesperetin, hesperetin-containing extract, hesperidin and hesperidin-containing extract, as well as collagen peptide and vitamin C.
4. A barrier functional composition for promoting FLG gene expression in human epidermal keratinocytes, characterized by containing at least two of the group consisting of rosmarinic acid or a rosmarinic acid-containing extract, caffeic acid or a caffeic acid-containing extract, hesperetin or a hesperetin-containing extract, and hesperidin or a hesperidin-containing extract, as well as collagen peptide and vitamin C.
5. A barrier functional composition for promoting FLG gene expression in human epidermal keratinocytes, characterized by containing lemon balm extract, collagen peptide and vitamin C.
6. A barrier functional composition described in any one of claims 1 to 5 that can be taken orally.
Citation Information
Patent Citations
Skin beautifying agent, and beauty and health food
JP2004238365A
Ceramide synthesis promoter, skin barrier function-ameliorating agent, and agent for preventing and treating disease caused by ceramide synthesis trouble
JP2008255051A
Skin care preparation, oral composition, and food and drink
JP2009242309A
Claudin production promoter, occludin production promoter and skin barrier function-improving agent
JP2009256244A
Granular or powder formulation containing collagen peptide and vitamin c
JP2012110239A
